Company intelligence / Profile preview

Positrigo

Ownership: Private
Development stage: Commercial

Overview

The company’s first product, NeuroLF, received FDA clearance in July 2024 as an ultra‑compact dedicated brain PET scanner. It enables accessible and cost-effective functional brain imaging for the diagnosis of Alzheimer’s disease and other neurological conditions. Production has started to scale with strong demand and pre-orders globally. Regulatory approval in Europe was anticipated by late 2024.

Therapeutic areas: OncologyNeurology
Modalities: DeviceDiagnostic imaging device (Positron Emission Tomography)
Industry: Medical Imaging

Partnerships

Well-established manufacturing partners supporting production scale-up (specific names not disclosed)

Beyond the preview

Go deeper on Positrigo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Positrigo.

Explore the full profile